Erythropoietin response to post-liver transplantation anemia

Sotirios Vasilopoulos, Robert Hally, Jaime Caro, Paul Martin, Sharon Westerberg, Michael Moritz, Bruce Jarrell, Santiago Muñoz

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Anemia frequently accompanies end-stage liver disease. Erythropoietin has recently been shown to be of benefit in a number of diseases complicated by anemia. We studied erythropoietin levels before and after orthotopic liver transplantation (OLT) and correlated these with the degree of anemia. Twenty- seven patients with end-stage cirrhosis who underwent OLT had preoperative and weekly postoperative serum erythropoietin levels determined by a highly sensitive radioimmunoassay. The relation of erythropoietin level to the values for hematocrit, serum creatinine, and cyclosporine and other biochemical test results was evaluated. Before transplantation, 23 patients were anemic; erythropoietin levels were appropriately elevated (72.7 ± 37 mU/mL; normal, 10 to 15 mU/mL) for the degree of anemia (hematocrit, 33.1% ± 1%) in 16 patients (70%). A blunted erythropoietin response to anemia was found in 7 of the anemic patients with cirrhosis (30%). After OLT, the hematocrit decreased to 29.5% ± 0.6% at 4 weeks, with a reciprocal increase in serum erythropoietin levels to 36 ± 5 mU/mL. Erythropoietin response appeared appropriate to the degree of anemia in 82% of the liver transplant recipients and blunted in 18%. We conclude that the ability to secrete erythropoietin in response to anemia is defective in many patients with end- stage liver disease, and a normal response may be restored after OLT. The results suggest that exogenous erythropoietin administration may be beneficial in anemic patients with cirrhosis and liver transplant recipients who have inappropriately low serum erythropoietin levels.

Original languageEnglish
Pages (from-to)349-355
Number of pages7
JournalLiver Transplantation
Volume6
Issue number3
StatePublished - May 1 2000
Externally publishedYes

Fingerprint

Erythropoietin
Liver Transplantation
Anemia
Hematocrit
End Stage Liver Disease
Serum
Fibrosis
Liver Cirrhosis
Cyclosporine
Radioimmunoassay
Creatinine
Transplantation
Liver

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Vasilopoulos, S., Hally, R., Caro, J., Martin, P., Westerberg, S., Moritz, M., ... Muñoz, S. (2000). Erythropoietin response to post-liver transplantation anemia. Liver Transplantation, 6(3), 349-355.

Erythropoietin response to post-liver transplantation anemia. / Vasilopoulos, Sotirios; Hally, Robert; Caro, Jaime; Martin, Paul; Westerberg, Sharon; Moritz, Michael; Jarrell, Bruce; Muñoz, Santiago.

In: Liver Transplantation, Vol. 6, No. 3, 01.05.2000, p. 349-355.

Research output: Contribution to journalArticle

Vasilopoulos, S, Hally, R, Caro, J, Martin, P, Westerberg, S, Moritz, M, Jarrell, B & Muñoz, S 2000, 'Erythropoietin response to post-liver transplantation anemia', Liver Transplantation, vol. 6, no. 3, pp. 349-355.
Vasilopoulos S, Hally R, Caro J, Martin P, Westerberg S, Moritz M et al. Erythropoietin response to post-liver transplantation anemia. Liver Transplantation. 2000 May 1;6(3):349-355.
Vasilopoulos, Sotirios ; Hally, Robert ; Caro, Jaime ; Martin, Paul ; Westerberg, Sharon ; Moritz, Michael ; Jarrell, Bruce ; Muñoz, Santiago. / Erythropoietin response to post-liver transplantation anemia. In: Liver Transplantation. 2000 ; Vol. 6, No. 3. pp. 349-355.
@article{c9b97d9bcdfb4c39b9115b9a802d769c,
title = "Erythropoietin response to post-liver transplantation anemia",
abstract = "Anemia frequently accompanies end-stage liver disease. Erythropoietin has recently been shown to be of benefit in a number of diseases complicated by anemia. We studied erythropoietin levels before and after orthotopic liver transplantation (OLT) and correlated these with the degree of anemia. Twenty- seven patients with end-stage cirrhosis who underwent OLT had preoperative and weekly postoperative serum erythropoietin levels determined by a highly sensitive radioimmunoassay. The relation of erythropoietin level to the values for hematocrit, serum creatinine, and cyclosporine and other biochemical test results was evaluated. Before transplantation, 23 patients were anemic; erythropoietin levels were appropriately elevated (72.7 ± 37 mU/mL; normal, 10 to 15 mU/mL) for the degree of anemia (hematocrit, 33.1{\%} ± 1{\%}) in 16 patients (70{\%}). A blunted erythropoietin response to anemia was found in 7 of the anemic patients with cirrhosis (30{\%}). After OLT, the hematocrit decreased to 29.5{\%} ± 0.6{\%} at 4 weeks, with a reciprocal increase in serum erythropoietin levels to 36 ± 5 mU/mL. Erythropoietin response appeared appropriate to the degree of anemia in 82{\%} of the liver transplant recipients and blunted in 18{\%}. We conclude that the ability to secrete erythropoietin in response to anemia is defective in many patients with end- stage liver disease, and a normal response may be restored after OLT. The results suggest that exogenous erythropoietin administration may be beneficial in anemic patients with cirrhosis and liver transplant recipients who have inappropriately low serum erythropoietin levels.",
author = "Sotirios Vasilopoulos and Robert Hally and Jaime Caro and Paul Martin and Sharon Westerberg and Michael Moritz and Bruce Jarrell and Santiago Mu{\~n}oz",
year = "2000",
month = "5",
day = "1",
language = "English",
volume = "6",
pages = "349--355",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Erythropoietin response to post-liver transplantation anemia

AU - Vasilopoulos, Sotirios

AU - Hally, Robert

AU - Caro, Jaime

AU - Martin, Paul

AU - Westerberg, Sharon

AU - Moritz, Michael

AU - Jarrell, Bruce

AU - Muñoz, Santiago

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Anemia frequently accompanies end-stage liver disease. Erythropoietin has recently been shown to be of benefit in a number of diseases complicated by anemia. We studied erythropoietin levels before and after orthotopic liver transplantation (OLT) and correlated these with the degree of anemia. Twenty- seven patients with end-stage cirrhosis who underwent OLT had preoperative and weekly postoperative serum erythropoietin levels determined by a highly sensitive radioimmunoassay. The relation of erythropoietin level to the values for hematocrit, serum creatinine, and cyclosporine and other biochemical test results was evaluated. Before transplantation, 23 patients were anemic; erythropoietin levels were appropriately elevated (72.7 ± 37 mU/mL; normal, 10 to 15 mU/mL) for the degree of anemia (hematocrit, 33.1% ± 1%) in 16 patients (70%). A blunted erythropoietin response to anemia was found in 7 of the anemic patients with cirrhosis (30%). After OLT, the hematocrit decreased to 29.5% ± 0.6% at 4 weeks, with a reciprocal increase in serum erythropoietin levels to 36 ± 5 mU/mL. Erythropoietin response appeared appropriate to the degree of anemia in 82% of the liver transplant recipients and blunted in 18%. We conclude that the ability to secrete erythropoietin in response to anemia is defective in many patients with end- stage liver disease, and a normal response may be restored after OLT. The results suggest that exogenous erythropoietin administration may be beneficial in anemic patients with cirrhosis and liver transplant recipients who have inappropriately low serum erythropoietin levels.

AB - Anemia frequently accompanies end-stage liver disease. Erythropoietin has recently been shown to be of benefit in a number of diseases complicated by anemia. We studied erythropoietin levels before and after orthotopic liver transplantation (OLT) and correlated these with the degree of anemia. Twenty- seven patients with end-stage cirrhosis who underwent OLT had preoperative and weekly postoperative serum erythropoietin levels determined by a highly sensitive radioimmunoassay. The relation of erythropoietin level to the values for hematocrit, serum creatinine, and cyclosporine and other biochemical test results was evaluated. Before transplantation, 23 patients were anemic; erythropoietin levels were appropriately elevated (72.7 ± 37 mU/mL; normal, 10 to 15 mU/mL) for the degree of anemia (hematocrit, 33.1% ± 1%) in 16 patients (70%). A blunted erythropoietin response to anemia was found in 7 of the anemic patients with cirrhosis (30%). After OLT, the hematocrit decreased to 29.5% ± 0.6% at 4 weeks, with a reciprocal increase in serum erythropoietin levels to 36 ± 5 mU/mL. Erythropoietin response appeared appropriate to the degree of anemia in 82% of the liver transplant recipients and blunted in 18%. We conclude that the ability to secrete erythropoietin in response to anemia is defective in many patients with end- stage liver disease, and a normal response may be restored after OLT. The results suggest that exogenous erythropoietin administration may be beneficial in anemic patients with cirrhosis and liver transplant recipients who have inappropriately low serum erythropoietin levels.

UR - http://www.scopus.com/inward/record.url?scp=0034029754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034029754&partnerID=8YFLogxK

M3 - Article

C2 - 10827238

AN - SCOPUS:0034029754

VL - 6

SP - 349

EP - 355

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 3

ER -